Welcome to our dedicated page for Arcturus Therape SEC filings (Ticker: ARCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) files regular reports and current disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed commercial mRNA medicines and vaccines company. On this page, you can review ARCT SEC filings such as annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other documents that detail its financial condition, clinical progress and corporate actions.
Arcturus uses its SEC filings to describe its focus on liver and respiratory rare disease therapeutics and infectious disease vaccines, including RNA therapeutic candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF) and partnered mRNA vaccine programs for SARS-CoV-2 and influenza. Forms 10-K and 10-Q typically discuss revenue sources from license fees, consulting and technology transfer fees, collaboration payments and grants, as well as research and development and general and administrative expenses tied to programs such as ARCT-032, ARCT-810, KOSTAIVE®, ARCT-2138 and ARCT-2304.
Current reports on Form 8-K provide timely information on material events, including clinical data releases, collaboration developments, regulatory updates for KOSTAIVE and other vaccine candidates, and changes in executive leadership or board composition. Other filings, such as Form 12b-25 notifications, explain any delays in periodic report submissions and confirm expected filing dates.
Stock Titan enhances access to ARCT filings by pairing real-time EDGAR updates with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q reports, as well as notable items in 8-Ks. Users can quickly see disclosures relevant to Arcturus mRNA platforms, collaboration structures, cash position and risk factors, and can also monitor insider-related information when Forms 3, 4 or 5 are available, all in one organized view.
Arcturus Therapeutics Holdings Inc. reported that its Chief Financial Officer, Dennis Mulroy, received a grant of employee stock options covering 100,000 shares of common stock. These options have an exercise price of $8.63 per share and expire on May 1, 2036.
The grant was made under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan as part of equity compensation. The underlying shares vest 25% on May 1, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, encouraging longer-term alignment with shareholders.
Arcturus Therapeutics Holdings Inc. filed an initial Form 3 for Chief Financial Officer Dennis Mulroy. The filing lists no reportable transactions or derivative positions, and no holdings entries are shown, serving purely as a baseline statement of beneficial ownership status.
Arcturus Therapeutics reported Q1 2026 revenue of $2.1 million, sharply down from $29.4 million a year earlier, mainly due to lower collaboration revenue from CSL Seqirus and reduced BARDA grant revenue. Net loss widened to $27.0 million, or $0.95 per share, from $14.1 million.
Operating expenses fell as research and development dropped to $21.5 million and general and administrative to $9.5 million, reflecting lower LUNAR‑COVID spending, BARDA activity, headcount and stock‑based compensation. Arcturus ended the quarter with $213.4 million in cash, cash equivalents and restricted cash and no debt, and believes this will fund operations for at least the next twelve months.
Clinically, the company advanced its rare‑disease RNA therapeutics: Phase 2 dosing progressed for cystic fibrosis candidate ARCT‑032 and enrollment continued in the Phase 2 OTC‑deficiency study ARCT‑810, with recent FDA feedback outlining steps toward a pivotal pediatric trial. Its partnered sa‑mRNA COVID‑19 vaccine KOSTAIVE gained UK marketing authorization, while collaboration partner CSL Limited recorded an approximately $430 million accounting write‑down related to the relationship, underscoring uncertainty around long‑term COVID‑19 vaccine demand and regulatory pathways.
Arcturus Therapeutics reported first quarter 2026 revenue of $2.1 million, down sharply from $29.4 million a year earlier, as it pivots from infectious disease vaccines toward rare disease programs. Total operating expenses fell to $31.0 million from $46.2 million, reflecting lower COVID-related manufacturing and trial costs.
The company posted a net loss of about $27.0 million, or ($0.95) per share, compared to a $14.1 million loss, or ($0.52) per share, in the prior-year quarter. Cash, cash equivalents and restricted cash were $213.4 million as of March 31, 2026, supporting a stated cash runway beyond the second quarter of 2028.
Arcturus initiated enrollment earlier than expected in a 12‑week open-label Phase 2 cystic fibrosis study and obtained FDA direction on the pediatric path for its ornithine transcarbamylase deficiency program ahead of an End of Phase 2 meeting in the second half of 2026. The company also appointed Dennis Mulroy as Chief Financial Officer, with a $520,000 base salary, up to 40% bonus eligibility, and options for 100,000 shares vesting over four years, plus severance and change‑in‑control protections.
Arcturus Therapeutics Holdings Inc. Schedule 13G/A shows ARK Investment Management LLC and Catherine D. Wood report beneficial ownership of 2,947,556 shares of Common Stock, representing 10.37% of the class. ARK holds sole voting and dispositive power over 2,947,556 shares; Catherine D. Wood holds shared voting and dispositive power over the same amount. Signatures dated 05/07/2026 appear on the amendment.
Arcturus Therapeutics Holdings Inc. is asking stockholders to vote at its fully virtual 2026 annual meeting on June 5, 2026 at 9:00 a.m. Pacific Time. Holders of 28,423,069 common shares as of April 14, 2026 can elect eight directors, approve on a non-binding advisory basis named executive officer compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026. The meeting will be held online via https://www.cstproxy.com/arcturusrx/2026, with admission and voting procedures differing for registered and beneficial owners. The proxy explains quorum rules, broker non-votes, director independence, board committee structure, and outlines 2025 director fees and executive pay programs.
Arcturus Therapeutics Holdings Inc amendment to a Schedule 13G/A states that The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026 that caused disaggregated subsidiary reporting. The form is signed by Ashley Grim on 03/26/2026.
Arcturus Therapeutics Holdings Inc. outlines its mRNA medicines business, highlighting rare-disease therapeutics and vaccines built on its LUNAR lipid delivery and STARR self-amplifying mRNA platforms. Lead programs include ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency, both in Phase 2 with orphan and rare pediatric designations.
The company’s COVID-19 vaccine KOSTAIVE, partnered with CSL Seqirus, is approved in Japan, the European Union and the United Kingdom, with commercial sales underway in Japan. However, the FDA has required additional clinical endpoint efficacy data, indefinitely delaying a planned U.S. biologics license application for KOSTAIVE.
Arcturus also describes early-stage vaccine and oncology platforms, BARDA-funded H5N1 pandemic flu work, and support from the Cystic Fibrosis Foundation. CSL Limited recorded a $430 million accounting write-down related to the collaboration, and Arcturus has initiated arbitration seeking a milestone payment tied to European marketing authorization.
Arcturus Therapeutics reported weaker revenue but narrower losses for the fourth quarter and full year 2025, while advancing its mRNA rare disease pipeline and extending its cash runway. Full-year revenue fell to $82.0 million from $152.3 million, mainly due to lower collaboration revenue as CSL-related COVID-19 work shifted from development to commercialization.
Operating expenses dropped sharply to $158.3 million from $248.0 million, driven by lower LUNAR-COVID, LUNAR-FLU and LUNAR-CF program costs and an operational restructuring. Net loss improved to $65.8 million (basic and diluted loss of $2.40 per share) from $80.9 million (loss of $3.00 per share) a year earlier.
Quarterly revenue for Q4 2025 was $7.2 million, down from $22.8 million, while net loss was $29.1 million versus $30.0 million. Cash, cash equivalents and restricted cash totaled $232.8 million at December 31, 2025, and the company now expects its cash runway to extend into the second quarter of 2028, supported by a strategic refocus on core rare disease programs. Clinically, ARCT-032 showed generally safe and well tolerated results in a Phase 2 third cohort, and regulators have permitted a 12-week Phase 2 cystic fibrosis study to begin dosing in the first half of 2026.
Balyasny Asset Management and affiliated reporting persons filed an amended Schedule 13G indicating they no longer beneficially own Arcturus Therapeutics Holdings Inc. common stock. As of the event date of 12/31/2025, they report beneficial ownership of 0 shares, representing 0.00% of the outstanding common stock.
Each reporting entity and individual, including Balyasny Asset Management L.P., related Delaware entities, and Dmitry Balyasny, reports no sole or shared voting or dispositive power over any Arcturus shares. The filing also confirms their holdings are in the ordinary course of business and not for influencing control of the company.